Skip to content

Evaluating a Type 2 Diabetes Prevention Program

Evaluating a Brief Type 2 Diabetes Prevention Program With Greater Scalability

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05822648
Enrollment
62
Registered
2023-04-21
Start date
2023-04-15
Completion date
2024-04-22
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes, Type 2 Diabetes

Keywords

prevention, Type 2 Diabetes, prediabetes, group intervention

Brief summary

This study aims to test the effectiveness of a Type 2 Diabetes (T2D) prevention program for individuals who have been diagnosed with prediabetes compared to a T2D educational control group. Project health is an obesity prevention program and has produced a 42% to 53% reduction in future onset of overweight/obesity and also produced greater reductions in negative affect compared to assessment-only controls that persisted. Project Health has been adapted to prevent onset of T2D among individuals with prediabetes. The study aims to test the effectiveness of Project Health at reducing BMI, HbA1c levels, increase physical activity and improve glucose control.

Interventions

BEHAVIORALProject Health

Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.

We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The investigator and follow-up assessors will be blinded to condition

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Between the ages of 18 and 65 2. Overweight (BMI between 25 and 40 kg/m2) 3. Diagnosed with prediabetes, defined as having elevated HbA1c (5.7-6.4%).

Exclusion criteria

1. Not between the ages of 18 and 65 2. Not overweight (BMI between 25 and 40 kg/m2) 3. Not diagnosed with prediabetes, defined as having elevated HbA1c (5.7-6.4%).

Design outcomes

Primary

MeasureTime frameDescription
Body Mass Index (BMI) - Post-Testpost-test (immediately after completion of 6 week intervention)BMI will be assessed at post-test to see which intervention produced greater reductions in BMI
Body Mass Index (BMI) - 3-Month Follow-Up3-month follow-upBMI will be assessed at 3-month follow-up to see which intervention produced greater reductions in BMI
HbA1c at 3-month Follow-up3-month follow-upParticipants will complete an HbA1c test at 3-month follow-up to determine their pre-diabetes status
Fasting Plasma Glucose3-month follow-upParticipants will complete a fasting glucose test at 3-month follow-up to determine their pre-diabetes status
Percent Body Fat - Post-Testpost-test (immediately after completion of 6 week intervention)
Percent Body Fat - 3-Month Follow-Up3-month follow-up
Percent Lean Body Mass - Post-Testpost-test (immediately after completion of 6 week intervention)
Percent Lean Body Mass - 3-Month Follow-Up3-month follow-up

Countries

United States

Participant flow

Participants by arm

ArmCount
Intervention
Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle. Project Health: Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
30
Control
We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan Educational Video Control: We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
32
Total62

Baseline characteristics

CharacteristicInterventionControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
30 Participants32 Participants62 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants3 Participants7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
26 Participants29 Participants55 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
14 Participants19 Participants33 Participants
Race (NIH/OMB)
Black or African American
2 Participants0 Participants2 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants3 Participants5 Participants
Race (NIH/OMB)
White
11 Participants8 Participants19 Participants
Region of Enrollment
United States
30 participants32 participants62 participants
Sex: Female, Male
Female
21 Participants22 Participants43 Participants
Sex: Female, Male
Male
9 Participants10 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 300 / 32
other
Total, other adverse events
0 / 300 / 32
serious
Total, serious adverse events
0 / 300 / 32

Outcome results

Primary

Body Mass Index (BMI) - 3-Month Follow-Up

BMI will be assessed at 3-month follow-up to see which intervention produced greater reductions in BMI

Time frame: 3-month follow-up

ArmMeasureValue (MEAN)Dispersion
InterventionBody Mass Index (BMI) - 3-Month Follow-Up30.3 kg/m2Standard Deviation 6.5
ControlBody Mass Index (BMI) - 3-Month Follow-Up28.7 kg/m2Standard Deviation 5.5
Primary

Body Mass Index (BMI) - Post-Test

BMI will be assessed at post-test to see which intervention produced greater reductions in BMI

Time frame: post-test (immediately after completion of 6 week intervention)

ArmMeasureValue (MEAN)Dispersion
InterventionBody Mass Index (BMI) - Post-Test30.3 kg/m2Standard Deviation 6.6
ControlBody Mass Index (BMI) - Post-Test28.8 kg/m2Standard Deviation 5.3
Primary

Fasting Plasma Glucose

Participants will complete a fasting glucose test at 3-month follow-up to determine their pre-diabetes status

Time frame: 3-month follow-up

ArmMeasureValue (MEAN)Dispersion
InterventionFasting Plasma Glucose107 mg/dLStandard Deviation 12
ControlFasting Plasma Glucose108 mg/dLStandard Deviation 13
Primary

HbA1c at 3-month Follow-up

Participants will complete an HbA1c test at 3-month follow-up to determine their pre-diabetes status

Time frame: 3-month follow-up

ArmMeasureValue (MEAN)Dispersion
InterventionHbA1c at 3-month Follow-up5.8 percentStandard Deviation 0.4
ControlHbA1c at 3-month Follow-up6 percentStandard Deviation 0.4
Primary

Percent Body Fat - 3-Month Follow-Up

Time frame: 3-month follow-up

ArmMeasureValue (MEAN)Dispersion
InterventionPercent Body Fat - 3-Month Follow-Up38.3 percent body fatStandard Deviation 9.8
ControlPercent Body Fat - 3-Month Follow-Up37.8 percent body fatStandard Deviation 8
Primary

Percent Body Fat - Post-Test

Time frame: post-test (immediately after completion of 6 week intervention)

ArmMeasureValue (MEAN)Dispersion
InterventionPercent Body Fat - Post-Test39.2 percent body fatStandard Deviation 9.5
ControlPercent Body Fat - Post-Test38.4 percent body fatStandard Deviation 7.8
Primary

Percent Lean Body Mass - 3-Month Follow-Up

Time frame: 3-month follow-up

ArmMeasureValue (MEAN)Dispersion
InterventionPercent Lean Body Mass - 3-Month Follow-Up61.6 percent lean massStandard Deviation 9.7
ControlPercent Lean Body Mass - 3-Month Follow-Up62.2 percent lean massStandard Deviation 7.9
Primary

Percent Lean Body Mass - Post-Test

Time frame: post-test (immediately after completion of 6 week intervention)

ArmMeasureValue (MEAN)Dispersion
InterventionPercent Lean Body Mass - Post-Test60.9 percent lean massStandard Deviation 9.6
ControlPercent Lean Body Mass - Post-Test61.6 percent lean massStandard Deviation 7.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026